- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01465490
Monitoring and Feedback in Substance Abuse Treatment
This is a three-staged study to develop and evaluate a monitoring instrument and associated intervention, as follows:
Stage 1 - Develop and determine the reliability, validity, and sensitivity to change of a brief Multidimensional Monitoring Instrument (MMI) for clients in outpatient substance abuse treatment (SAT).
Stage 2 - Develop a Monitoring and Feedback Intervention (MFI) that uses the MMI. As part of this process, create a manual, training materials, and competence and adherence measures, and conduct a feasibility study within an outpatient SAT unit to refine the intervention and associated materials and measures.
Stage 3 - Conduct a randomized clinical trial (RCT) to determine the preliminary efficacy of the MFI compared to treatment as usual (TAU) for clients in outpatient SAT. In this pilot study, it is hypothesized that the MFI will positively impact the treatment process, and short-term, during treatment, outcomes.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In Stage 1, 20 substance abuse treatment (SAT) professionals, including clinicians, supervisors, and administrators, will participate in clinical focus groups. Clinical focus group members will review and discuss the MMI, its potential uses, and specific strategies around its implementation. Also in Stage 1, 240 clients will participate in a formal psychometric evaluation study of the Multidimensional Monitoring Instrument (MMI). These participants will complete a study intake meeting, which will include providing locator information (to facilitate scheduling research appointments), a baseline ASI6, and the MMI. After this intake, participants will complete 5 additional MMIs during a 4-week period. At the one and two-month follow-up research meetings, participants will complete the ASI6 and provide specimens for urine drug screens (UDSs). To ensure adequate resource management, participants who leave treatment at the program will not be continued in the study. Participants who are incarcerated during the study will not be contacted while in custody.
In Stage 2, the Monitoring and Feedback Intervention (MFI), the MFI Manual, and associated training materials will be completed with expert consultation. Also in Stage 2, 35 clients will participate in the MFI Feasibility Study. They will complete a baseline ASI6, as well as brief research assessments at 1-month post study intake and 2 months later (i.e., at the conclusion of their participation). Client participants will also provide specimens for UDSs. Clients will complete the MMI with their counselors on a regular basis, about weekly. Five randomly selected counselors will also participate in the Feasibility Study. They will meet with research staff for training and to periodically complete questionnaires/interviews. All individual counseling sessions will be recorded using a digital voice recorder.
During Stage 3, 112 clients will participate in a randomized clinical trial (RCT) of the intervention (MFI). These participants will complete a baseline ASI6, as well as brief research assessments at 1-month post study intake and 2 months later (i.e., at the conclusion of their participation). They will also provide samples for UDSs. Clients will be randomized so that one-half will receive treatment as usual (TAU; with the exception that counseling sessions will be digitally recorded), and one-half will receive MFI. Clients in the MFI group will participate in standard treatment and complete the MMI weekly with their counselors at the beginning of each individual counseling session. Also, a total of 8 counselors will be randomly selected to participate. They will be randomized so that 4 will provide TAU, and 4 will provide MFI. All counselors will meet with research staff for training and to periodically complete questionnaires/interviews. All individual counseling sessions will be recorded using a digital voice recorder.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Presbyterian Medical Center
-
Philadelphia, Pennsylvania, United States, 19132
- Sobriety Through Outpatient
-
Philadelphia, Pennsylvania, United States, 19102
- Rehab After Work
-
Philadelphia, Pennsylvania, United States, 19146
- Jefferson Intensive Outpatient
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Client receiving intensive outpatient treatment at participating program
- Counselor employed by participating program
Exclusion Criteria:
- Client unable to speak English
- Client too cognitively impaired to give informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Treatment as usual
|
|
Experimental: Monitoring and Feedback Intervention
|
Clients participate in standard treatment and complete the MMI weekly with their counselors at the beginning of each individual counseling session.
Counselors have been trained to administer the MMI and will have access to the data to use during sessions.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment attendance
Time Frame: 3 months after consent
|
Client participant's treatment attendance is obtained from treatment program clinical record.
|
3 months after consent
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Urine screen results
Time Frame: 3 months after consent
|
Client participant's urine screen results are obtained from treatment program clinical record.
|
3 months after consent
|
Discharge status
Time Frame: 3 months after consent
|
Client participant's discharge status is obtained from treatment program clinical record.
|
3 months after consent
|
Discharge date
Time Frame: 3 months after consent
|
Client participant's discharge date is obtained from treatment program clinical record.
|
3 months after consent
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: John S Cacciola, Ph.D., Treatment Research Institute
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DA021154
- 5R01DA021154-03 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Substance Abuse
-
The Morton Center, Inc.National Institute on Alcohol Abuse and Alcoholism (NIAAA)UnknownAlcohol Dependence | Cannabis Dependence | Alcohol Abuse | Cannabis Abuse | Other Substance AbuseUnited States
-
National Health Promotion Associates, Inc.UnknownSubstance Use | Substance Abuse | Prescription Drug Abuse (Not Dependent)United States
-
Michael E. DeBakey VA Medical CenterUnknownAlcohol Dependence | Alcohol Abuse | Substance Abuse ProblemUnited States
-
National Health Promotion Associates, Inc.UnknownSubstance Use | Substance Abuse | Prescription Drug Abuse (Not Dependent)
-
National Institute on Drug Abuse (NIDA)CompletedDrug/Substance Abuse/Addiction | Alcohol Abuse/AddictionUnited States
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)CompletedSubstance Abuse, IntravenousUnited States
-
Sheidow Consulting, Inc.Oregon Social Learning CenterCompletedSubstance Abuse ProblemUnited States
-
Penn State UniversityCompletedSubstance Abuse ProblemUnited States
-
National Institute on Drug Abuse (NIDA)CompletedSubstance Abuse | Drug Abuse | Alcohol AbuseUnited States
-
University of California, IrvineUS Department of Veterans AffairsWithdrawn
Clinical Trials on Monitoring and Feedback Intervention
-
Shalvata Mental Health CenterUnknownPersonality Disorders | Psychotic Disorders | Anxiety Disorders | Affective DisordersIsrael
-
University of PennsylvaniaCompleted
-
Drexel UniversityAmerican College of Sports Medicine; Psi Chi; QualtricsCompletedObesity | Overweight | Physical Activity | Sedentary Lifestyle
-
Institut Català d'OncologiaFondazione IRCCS Istituto Nazionale dei Tumori, Milano; University of Aberdeen and other collaboratorsCompletedTobacco Use | Tobacco Smoking | Second Hand Tobacco Smoke
-
University of CambridgeUniversity of Leicester; City, University of LondonRecruitingAtrial Fibrillation | Paroxysmal Atrial FibrillationUnited Kingdom
-
University of PittsburghCompletedObesity | OverweightUnited States
-
Boris Kovatchev, PhDCompletedDiabetes Mellitus, Type 1United States
-
TNOWageningen University and Research; Google LLC.; Jumbo Supermarkten Bv.; Noldus...Completed
-
University of Mississippi Medical CenterActive, not recruiting
-
US Department of Veterans AffairsCompleted